Ensysce Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held on August 24, 2023. The report was filed on August 28, 2023. Ensysce Biosciences, Inc. is a Delaware corporation with its principal executive offices in La Jolla, California, and its common stock trades on The Nasdaq Stock Market LLC under the symbol ENSC.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and stockholder voting results.
Material Changes and Voting Results
Three proposals were submitted to stockholders, all of which were approved:
- Director Elections: Stockholders elected two Class II Directors with terms expiring in 2026: Bob Gower and Curtis Rosebraugh. Both nominees received a majority of votes cast "FOR" their election.
- Equity Incentive Plan Amendment: Stockholders approved an amendment to the Amended and Restated 2021 Omnibus Incentive Plan. The aggregate number of shares available for issuance under the plan was increased from 31,296 shares to 617,092 shares.
- Auditor Ratification: Stockholders ratified the appointment of Moss Adams LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verification of the increased share pool (617,092 shares) available under the 2021 Omnibus Incentive Plan and its potential dilution impact.
- Confirmation of the re-election of Bob Gower and Curtis Rosebraugh to the Board of Directors.
- Confirmation that Moss Adams LLP remains the independent auditor for the 2023 fiscal year.